Pharmaceutical

Numinus will manage two new clinics in Montreal and Vancouver to host trials.

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has secured two new Canadian psychedelic clinics that will host the Canadian sites of the MAPS Public Benefit Corporation (MAPS PBC) study "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)."

Numinus Logo (CNW Group/Numinus Wellness Inc.)

In addition to managing the two new clinics, which are fully compliant with Health Canada regulations and ready to provide MDMA-assisted therapy as part of the trial, Numinus will host the Montreal and Vancouver sites in MAPPUSX, which will continue to study the safety and efficacy of MDMA in treating severe PTSD, under the leadership of MAPS PBC as study organizer. Numinus will also financially support costs relating to therapists who deliver the therapeutic intervention in Numinus clinics during the trial.

"We are honored to host the Canadian sites of the MAPPUSX trial as we continue to examine the important findings around MDMA-assisted therapy for PTSD," said Dr. Joe Flanders , VP, Psychology, Numinus and therapist for the Montreal site of the trial. "Our clinical and research teams are well positioned to implement MAPS' research and, ultimately, to work with MAPS on the translation of research findings into mainstream clinical practice. We are excited about this study in both BC and Quebec and look forward to how the MAPPUSX study supports expanded collaboration in the future."

To date, 25 Numinus-affiliated therapists have gone through MAPS' training program for delivery of MDMA-assisted therapy and a number of these therapists will have roles in the trial. The trial will be open to eligible participants who were previously enrolled in the placebo arm of the parent study (MAPP1) or who were not able to receive treatment due to COVID-19 restrictions.

"We are happy to work with a trusted ally to quickly complete the extension trial at the Canadian sites" said Rick Doblin , Ph.D. the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS).  "As we get closer to our goal of making MDMA-assisted therapy a reality, it is critical that we work with clinics who will advance making this treatment widely accessible in real-world settings."

To accomplish this next step in the MAPPUSX study, Numinus has assumed the leases of two new clinics, the Vancouver and Montreal psychedelic-assisted psychotherapy clinics that were previously used to conduct MAPS PBC's earlier study "A multi-site phase 3 study of MDMA-assisted psychotherapy for PTSD (MAPP1)." In that trial, 88% of participants experienced a clinically meaningful reduction in symptoms and 67% no longer qualified for a PTSD diagnosis. The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD

Payton Nyquvest , CEO, Numinus, added, "We are thrilled that our two new locations, which are purpose-developed for psychedelic-assisted therapy, regulatorily compliant and leading in industry standards, can be used to help advance this crucial work on psychedelic medicine. We look forward to deepening our collaboration with MAPS while expanding the resources and solutions available to those suffering from PTSD."

Securing the Canadian sites will further allow Numinus to expand its clinical activities in Quebec and BC, including its ketamine-assisted psychotherapy program, which is available in both provinces.

NOTE
The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by Health Canada or the U.S. Food and Drug Administration (FDA), does not work for everyone, and carries risks even in therapeutic settings. These statements are no guarantee of future Health Canada or FDA approval or availability of MDMA-assisted therapy. These statements necessarily involve known and unknown risks and uncertainties, which may cause actual outcomes to differ materially from projections.

About Numinus
Numinus Wellness (TSXV: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn , Facebook , Twitter , and Instagram .

About MAPS
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised over $130 million for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator . Learn more at maps.org

ABOUT MAPS PUBLIC BENEFIT CORPORATION (MAPS PBC)
MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics while prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. Learn more at www.mapspublicbenefit.org

Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's limited operating and profitability track record; dependence on management; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/numinus-to-host-extension-of-maps-sponsored-mdma-assisted-therapy-for-ptsd-trials-301420678.html

SOURCE Numinus Wellness Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/10/c1146.html

News Provided by Canada Newswire via QuoteMedia

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Curaleaf began serving New Jersey adult-use customers at its Bellmawr location in April

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, will begin adult-use sales at its Edgewater Park, New Jersey dispensary on May 25 . Located at 4237 US-130, Curaleaf Edgewater Park is now the Company's second location to sell adult-use cannabis in the Garden State.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Appoints Tyneeha Rivers As Chief People Officer

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf'' or the "Company"), a leading international provider of consumer products in cannabis, announced today that Tyneeha Rivers has been appointed to the role of Chief People Officer for Curaleaf, a new position.

The move follows the recent announcement of Matt Darin being named CEO, replacing Joe Bayern , who will be launching a new CPG focused division of the Company.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
AgriForce to Present at the H.C. Wainwright Global Investment Conference on May 25th

AgriForce to Present at the H.C. Wainwright Global Investment Conference on May 25th

AGRIFORCE Growing Systems Ltd. ("the Company") (NASDAQ: AGRI; AGRIW) an intellectual property (IP)-focused AgTech company dedicated to advancing sustainable cultivation and crop processing across multiple verticals, today announced that Ingo Mueller, Chief Executive Officer of AGRIForce, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel, Miami FL. The conference will include virtual and in-person participation.

Mr. Mueller is scheduled to present in-person on Wednesday, May 25, 2022 at 12:00 p.m. ET. Management will also be available for one-on-one meetings with qualified investors throughout the conference.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
person working on laptop

Cannabis Weekly Round-Up: Cresco and Columbia Care Share Q1 Financials

A pair of US cannabis companies that are tied together by an acquisition plan released their quarterly financials this week. Cannabis delivery services were in focus as well as two companies confirmed their plans to offer seamless delivery solutions for cannabis consumers.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

Canopy Growth Kicks Off Summer Long Weekends with Exciting New Product Line-Up

Canadian cannabis market leader introduces new offerings across its house of brands 7ACRES, Ace Valley, Deep Space and Doja

SMITHS FALLS, ON , May 20, 2022 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, hemp, and cannabis device company, today unveiled a line-up of new offerings across its premium brand portfolio – 7ACRES, Ace Valley, Deep Space and Doja. With select products releasing just in time for the first long weekend of the summer, including the release of its first large format premium flower offering for the recreational market, Doja 91K 14g, this new line-up builds on the Company's continued commitment to product innovation and meeting evolving consumer demand, while cementing Canopy's leadership position in the premium flower market.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
pair of hands holding cannabis buds

Lift Expo Show Floor Marked by Calls for Cannabis Action and Unity

The most recent edition of the Lift & Co. Expo, held this past weekend in Toronto, brought multiple calls to action among cannabis industry stakeholders.

In panels at the show and in conversations with the Investing News Network (INN), experts used this year’s event to urge all types of cannabis companies to collaborate in high-level lobbying.

During the event, a distinct theme appeared: the need for firms in the cannabis market to better advocate for themselves in front of the Canadian government.

Keep reading...Show less

Latest Press Releases

Related News

×